<DOC>
	<DOC>NCT00314041</DOC>
	<brief_summary>Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines. Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory</brief_summary>
	<brief_title>Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infants 710 weeks of age eligible to receive routine immunization</criteria>
	<gender>All</gender>
	<minimum_age>7 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Infant</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Meningococcal</keyword>
	<keyword>Antibody</keyword>
	<keyword>Immune memory</keyword>
	<keyword>Health</keyword>
	<keyword>Meningococcal Vaccines</keyword>
</DOC>